−0.3%
since Sep 30
The idea
I believe the winners of gene editing and AI-designed drugs will mostly be the incumbents, not the small disruptors, since the majors control trial infrastructure, regulatory relationships, and global sales forces needed to get breakthroughs to patients. So this take holds the pharma companies with the deepest late-stage pipelines, weighted heaviest toward the metabolic and obesity leaders, then spread across oncology, immunology, genetic medicine, and vaccines, with no single name dominating.
What it owns
- Cancer treatment remains where the most pipeline investment flows in pharma, and these majors have the deepest late-stage oncology programs. · AstraZenecaIt maintains the deepest late-stage oncology pipeline among major pharma companies and has invested directly in emerging genetic medicine companies., Merck & Co.Its pipeline strategy focuses on next-generation cancer therapies to replace blockbuster drugs facing patent cliffs., NovartisIt leads in radioligand cancer therapy, a specialized modality that requires manufacturing and delivery infrastructure only a major company owns., GenmabIts antibody technology platform supports drugs across the industry while building its own late-stage oncology pipeline for direct commercialization.22%
- Immune-disease drugs form the most durable franchises in medicine, and these companies keep replacing their own blockbuster drugs. · AbbVieIt successfully replaced its largest franchise with new drugs from its own pipeline, demonstrating the ability to compound through self-renewal., Johnson & JohnsonIts immunology and cell therapy pipelines require the trial and commercial infrastructure that only a major pharmaceutical company can provide., ArgenxIt scaled an autoimmune therapy across multiple diseases using trial infrastructure and partnerships with larger pharmaceutical companies., SanofiIts leading immunology drug continues expanding into new disease areas through late-stage pipeline work typical of an incumbent company.21%
- The obesity drug franchise is the largest profit engine in pharma today, and the leading companies in this market control most of it. · Eli LillyIts obesity franchise compounds through multiple pipeline candidates in different formats, showing the incumbent advantage in controlling the category., Novo NordiskIt is the second incumbent in metabolic disease and developing oral versions of its drugs to sustain leadership in the fastest-growing category., AmgenIt acquired a monthly-dose obesity drug with late-stage data showing it can compete with the market leaders in this category.20%
- Large biotechs have already turned genetic science into approved, profitable drugs, making them the established players in this field. · Vertex PharmaceuticalsIt owns dominant positions in cystic fibrosis and brought the first CRISPR therapy to market, demonstrating scale that smaller gene editors cannot match., Regeneron PharmaceuticalsIt built a genetics-driven discovery engine within a major pharma structure, combining innovation with manufacturing and commercial reach., Alnylam PharmaceuticalsIt transformed RNAi from research into a commercial platform for gene-silencing drugs, becoming a large-scale biotech in its own right.16%
- Leaders in HIV, vaccines, and new neurological drugs have achieved recent pipeline wins that the market undervalues. · Gilead SciencesIts virology pipeline produced a twice-yearly HIV prevention drug that represents genuine innovation in an established treatment area., GSKIt holds global leadership in vaccines and HIV treatment through manufacturing and distribution scale that only a major company can sustain., Bristol-Myers SquibbIt acquired an innovative neurological drug with a new mechanism and now markets it through its existing commercial infrastructure.13%
- Cash8%